John Dunlop, Ph.D.
John Dunlop is the Head of Research and Development of Neumora. Prior to Neumora, John was most recently at Amgen, where he led the neuroscience research program responsible for therapeutic discovery activities in neurodegenerative diseases, pain and migraine. Prior to Amgen, he led neuroscience discovery and early development at AstraZeneca and previously held executive leadership roles in neuroscience at Wyeth and Pfizer.
Trained as a neuropharmacologist, John’s research interests include the role of protein quality control mechanisms, innate immunity and mitochondrial dysfunction in brain diseases. John is an industry member of the HEAL (Helping End Addiction Long term) Partnership Committee, an NIH advisory committee established to support NIH initiatives launched to address the nation’s opioid crisis. He is a board member of Target-ALS, a non-profit enterprise dedicated to accelerating drug discovery and development in ALS, and MassBio, and is on the scientific advisory boards of Vigil Neuroscience and the Packard Center for ALS Research at Johns Hopkins.
John holds a B.Sc. in biochemistry from the University of Glasgow and a Ph.D. in neuroscience from the University of St. Andrews.